Inhibition of SRPK1 and SRPK2 has been explored as a potential therapy for HIV infection with limited success; however, these compounds may also prove useful for further exploring the BLRF2’s role in EBV replication [35]. This evidence concerns the gene SRPK2 and HIV infectious disease.